[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"TIPMED Medical Device Manufacturing Ltd. Co.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645227",false,"NCT07678034","Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System","A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Male or female participants,\n* Participants who have undergone Reverse Shoulder Arthroplasty or Shoulder Hemiarthroplasty for any valid indication,\n* Participants in whose surgical procedure the Tipmed™ Shoulder Prosthesis System product configurations were utilized.\n* Participants who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship).\n* Participants who have voluntarily signed the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Concurrent participation in any other interventional clinical trial.","ALL","18 Years",{"count":18,"type":19},54,"ESTIMATED","OBSERVATIONAL","This study is designed as a prospective, multicenter, observational post-market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the Tipmed™ Shoulder Prosthesis System at 12 months postoperatively. The study population includes adult patients who undergo reverse shoulder arthroplasty (RSA) or shoulder hemiarthroplasty (HA) using the Tipmed™ implant systems due to various clinical indications such as osteoarthritis, rotator cuff arthropathy, or proximal humerus fractures. The main objective is to gather real-world clinical evidence on the 12-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.",[23,24,25,26,27],"Glenohumeral Osteoarthritis","Proximal Humerus Fracture","Rotator Cuff Arthropathy","Rheumatoid Arthritis","Avascular Necrosis",[29,30,31,32,33],"Reverse Shoulder Arthroplasty","Shoulder Prosthesis","Shoulder Hemiarthroplasty","Post-Market Clinical Follow-Up (PMCF)","Modified Constant-Murley Score","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2025-06-16",{"date":42,"type":19},"2030-06-15",{"name":44,"class":45},"TIPMED Medical Device Manufacturing Ltd. Co.","INDUSTRY",4,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100641087","NCT07653295","Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System","A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Male or female participants,\n* Participants who have undergone Revision Hip Arthroplasty (either total revision or partial component revision) for any indication (such as a documented joint failure or prosthesis-related clinical complication),\n* Participants in whose revision procedure the Tıpmed™ Revision Hip Prosthesis System components were utilized,\n* Participants who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship),\n* Participants who have voluntarily signed the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Subjects currently participating in any other interventional clinical trial.",{"count":54,"type":19},35,"This is a multicenter, prospective, observational, post-market clinical follow-up (PMCF) study designed to evaluate the safety and clinical performance of the Tipmed™ Revision Hip Prosthesis System in adult participants undergoing revision hip arthroplasty. The study aims to gather real-world clinical evidence on the 24-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.",[57,58,59,60,61,62],"Revision Hip Arthroplasty","Aseptic Loosening of Prosthetic Joint","Prostheses-related Infections","Joint Instability","Periprosthetic Fractures","Prosthesis Failure",[64,57,65,32,66],"Hip Prosthesis","Revision Hip Prosthesis","Harris Hip Score (HHS)","2026-06-17",{"date":69,"type":38},"2026-06-18",{"date":71,"type":38},"2024-03-12",{"date":73,"type":19},"2029-03-31",{"name":44,"class":45},{"id":76,"slug":4,"hasResults":10,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":99,"locationsCount":46},"100641958","NCT07651735","Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Primary Hip Prosthesis System","A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Primary Hip Prosthesis System","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Male or female participants,\n* Subjects who have undergone Primary Hip Arthroplasty (either total or partial) for any indication,\n* Subjects in whose surgical procedure the Tipmed™ Primary Hip Prosthesis System components were utilized.\n* Subjects who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship).\n* Subjects who have voluntarily signed the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Subjects currently participating in any other interventional clinical trial.",{"count":82,"type":19},101,"This is a multicenter, prospective, observational, post-market clinical follow-up (PMCF) study designed to evaluate the safety and clinical performance of the Tipmed™ Primary Hip Prosthesis System in adult subjects undergoing primary hip arthroplasty. The study aims to gather real-world clinical evidence on the 24-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.",[85,86,87,88,89],"Total Hip Arthroplasty (THA)","Hemiarthroplasty","Osteoarthritis (OA) of the Hip","Femoral Neck Fractures","Joint Diseases",[64,91,92,93,32,66],"Total Hip Prosthesis","Partial Hip Prosthesis","Primary Hip Arthroplasty","2026-06-10",{"date":96,"type":38},"2026-06-16",{"date":71,"type":38},{"date":73,"type":19},{"name":44,"class":45},""]